摘要
目的:观察沙库巴曲缬沙坦治疗射血分数降低的慢性心力衰竭的临床效果。方法:选取2020年6月—2021年12月中山大学附属第三医院粤东医院收治的慢性射血分数降低的心力衰竭患者115例,按照随机数字表法分为对照组(n=59例),观察组(n=56例)。对照组仅采用常规治疗,观察组在对照组的基础上口服沙库巴曲缬沙坦片。对比两组治疗前及治疗后6个月左心室射血分数(LVEF)改善情况以及测定血浆N末端脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、6 min步行距离(6MWT)水平的变化。结果:观察组总有效率(83.93%)高于对照组(69.49%),差异有统计学意义(P<0.05)。治疗6个月后,两组的NT-proBNP、hs-CRP、TNF-α均较治疗前降低,LVEF较治疗前升高,且观察组上述指标改善情况优于对照组,差异有统计学意义(P<0.05);两组的SMWT较治疗前增高,差异有统计学意义(P<0.05),观察组6MWT长于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率(12.5%)低于对照组(13.5%),但差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦治疗射血分数降低的慢性心力衰竭的临床疗效较好,且具有安全性。
Objective Clinical efficacy of Sacubatrovalsartan in the treatment of chronic heart failure with reduced ejection fraction.Methods A total of 115 patients with heart failure with reduced chronic ejection fraction from the Third Affiliated Hospital of Sun Yat-sen University from June 2020 to December 2021 were enrolled and divided into control group(n=59 cases)and observation group(n=56 cases)according to the random number table method.The control group was treated only with conventional treatment,and the observation group took oral Sacubatrovalsartan tablets on the basis of the control group.The improvement of left ventricular ejection fraction(LVEF)before treatment and 6 months after treatment and the determination of plasma N-terminal brain natriuretic peptide precursor(NT-proBNP),hypersensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),and 6-minute walking distance(6MWT)levels were compared between the two groups.Results The total effective rate of the observation group(83.93%)was higher than that of the control group(69.49%),and the difference was statistically significant(P<0.05).After 6 months of treatment,the NT-proBNP,hs-CRP and TNF-αof the two groups were lower than before treatment,LVEF was higher than that before treatment,and the improvement in the observation group was better than that in the control group,with a statistically significant difference(P<0.05),the 6WMT in the two groups was higher than that of before treatment,the difference was statistically significant(P<0.05),the observation group 6MWT was longer than the control group,the difference was statistically significant(P<0.05),and the incidence of adverse reactions in the observation group(12.5%)was lower than that of the control group(13.5%),and the difference was not statistically significant(P>0.05).Conclusion Sacubatrovalsartan has a good clinical efficacy and safety profile in the treatment of chronic heart failure with reduced ejection fraction.
作者
李建明
罗诗韵
谢志辉
LI Jianming;LUO Shiyun;XIE Zhihui(Department of Cardiovascular District 1,East Guangdong Hospital of The Third Affiliated Hospital of Sun Yat sen University,Meizhou,Guangdong 514000,China;Department of Internal Medicine,Meizhou Hospital of Traditional Chinese Medicine,Meizhou,Guangdong 514000,China)
出处
《医药前沿》
2022年第30期20-23,27,共5页
Journal of Frontiers of Medicine
关键词
射血分数低下
心力衰竭
沙库巴曲缬沙坦
炎症因子
心功能
Low ejection fraction
Heart failure
Sacubatrovalsartan
Inflammatory factors
Cardiac function
